Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8686347 | Neurobiology of Disease | 2018 | 22 Pages |
Abstract
Plasma total and nervous system derived exosomal (NDE) α-synuclein have been determined as potential biomarkers of Parkinson's disease (PD). To explore the utility of plasma α-synuclein in the prodromal phase of PD, plasma total and NDE α-synuclein were evaluated in baseline and 2-year follow-up samples from 256 individuals recruited as part of the Parkinson's Associated Risk Syndrome (PARS) study. The results demonstrated that baseline and longitudinal increases in total α-synuclein predicted progression of cognitive decline in hyposmic individuals with dopamine transporter (DAT) binding reduction. On the other hand, a longitudinal decrease in NDE α-synuclein predicted worsening cognitive scores in hyposmic individuals with DAT binding reduction. Finally, in individuals with faster DAT progression, decreasing NDE/total α-synuclein ratio was associated with a larger reduction in DAT from baseline to follow-up. These results suggest that, though underlying mechanisms remain to be defined, alterations in plasma total and NDE α-synuclein concentrations are likely associated with PD progression, especially in the aspect of cognitive impairment, at early stages of the disease.
Keywords
ProdromalsP-selectinMoCAGLMUPDRSMMSEDATα-SynBSAH&YSoluble P-selectinUPSITα-synucleinbovine serum albuminAlpha-synucleinDopamine transporterMini-Mental Status ExaminationSPECTAlzheimer's diseaseParkinson's diseasesingle-photon emission computed tomographyRiskUniversity of Pennsylvania Smell Identification TestCoefficient of VariationCSFCerebrospinal fluidGeneral linear modelHemoglobinHgbHoehn and YahrPARsParkinson's Plasma
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Hua Wang, Anzari Atik, Tessandra Stewart, Carmen Ginghina, Patrick Aro, Kathleen F. Kerr, John Seibyl, Danna Jennings, PARS Investigators PARS Investigators, Poul Henning Jensen, Kenneth Marek, Min Shi, Jing Zhang,